NCT02137889 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG

VAY736

VAY736 is a human immunoglobulin of the G class (IgG1/k) monoclonal antibody (mAb) designed to specifically bind the BAFF receptor. VAY736 binds primarily to B-cells through its fragment antigen binding (Fab) region, in human whole blood and spleen samples; it does not bind to natural killer (NK) cells, monocytes, dendritic cells, granulocytes, or platelets.

Trial Locations (2)

33612

H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer SC, Tampa

08035

Novartis Investigative Site, Barcelona